Lawrence Steinman

Lawrence J.
Steinman founded Nuon Therapeutics, Inc. in 2006, Neurocrine Biosciences, Inc. in 1997, where he worked as Director from 1997 to 2005, Bayhill Therapeutics, Inc. in 2001, where he worked as Director from 2010 to 2013, Atreca, Inc. in 2012, where he worked as Director from 2012 to 2019, Forum Markets, Inc. in 2013, where he worked as Director from 2024 to 2025, and Pasithea Therapeutics Corp.
in 2020, where he is working as Executive Chairman.
Dr. Steinman also founded Drumroll Health, Inc., Steinman Laboratory, Katexco Pharmaceuticals Corp., where he is working as Chairman, and Tolerion, Inc., where he worked as Executive Chairman from 2013 to 2020.
Dr. Steinman also currently works at CannBioRex Pharmaceuticals Corp., as Co-Chairman from 2018, 180 Life Corp., as Co-Chairman from 2019, BioAtla, Inc., as Lead Independent Director from 2020, Himalaya Therapeutics, as Director, National Academy of Sciences, as Member, National Academy of Medicine (United States), as Member, Pharnext SA, as Member-Supervisory Board from 2023, and Stanford University, as Professor from 2011.
Dr. Steinman also formerly worked at KBL Merger Corp.
IV, as Co-Executive Chairman, Stanford University School of Medicine, as Chairman-Interdepartmental Program from 2003 to 2011, Centocor, Inc., as Director from 1990 to 1998, and Neuronyx, Inc., as Director.
Dr. Steinman received his undergraduate degree in 1968 from Dartmouth College, doctorate degree in 2008 from Hasselt University, doctorate degree in 1973 from Harvard Medical School, and doctorate degree in 2022 from the University of Buenos Aires School of Medicine.